H
Huimei Technology
Huimei Technology is an artificial intelligence (AI)-powered medical solutions provider
About Huimei Technology
Founded in 2015, Huimei Technology, also known as Huimei Healthcare, operates as a medical artificial intelligence solutions provider. The company was established as a division of Huimei Healthcare Management Services, which was a 2015 joint venture between Hillhouse Capital and the U.S.-based Mayo Clinic. The founder and CEO is Zhang Qi, who previously served as the head of the algorithm team for Alibaba Group's Tmall platform. Zhang has stated that his motivation was to address the lag in medical quality management and patient safety by leveraging technology to overcome the shortcomings of traditional "experience medicine".
Huimei Technology's business is centered on developing AI-powered solutions to enhance clinical quality for healthcare providers. The company serves the hospital market, with its AI product portfolio covering over 1,200 graded hospitals in China, more than 70% of which are tertiary hospitals. Its business model involves providing these institutions with advanced software systems designed to improve diagnostics, data management, and overall medical service quality. The core of their offering is an AI-based medical quality control system that uses technologies like natural language processing and deep learning to analyze clinical big data.
The company's flagship product is Dr. Mayson, a clinical decision support system (CDSS). This system assists doctors by providing real-time diagnostic suggestions, medication guidance, and risk warnings directly within the clinical workflow. Dr. Mayson is designed to automate and improve Plan-Do-Check-Act (PDCA) cycles in healthcare management, covering pre-diagnosis to post-diagnosis stages. Other key products include a disease process quality management system, a medical knowledge base, and a smart VTE (venous thromboembolism) prevention and control system. For instance, the VTE system reportedly increased successful diagnoses by 85% at one Beijing hospital shortly after launch. To ensure clinical relevance, the company employs a team of over 30 full-time doctors to help design its algorithms.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Haidian, China
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, Medical Imaging, Core AI, Tech for Hospitals and Clinics, Clinical Decision Support, Hard Tech, AI Applications, DT and LS
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Client focus
- b2b
- Investment activity
- 4 companies, latest Jun 2024
- Capital deployed
- $72M
- Preferred round
- SERIES B
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $28M | $550M | Qiming Venture Partners · Eastern Bell Capital · Shanghai Science and Technology Innovation Center | ↗ |
| SERIES DOther financing | Jan 2024 | $9.9M | $550M | NRL Capital | ↗ |
Growth signals
Latest recorded traffic for Huimei Technology is 720 monthly website visits, up 500% over the last three months. Huimei Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Pukang Weixin BiotechnologyChinaSpecializing in polypeptide drug side chains and PEG derivatives
$110Mvaluation
Bio-EngineHuangpu, China
$248Mvaluation
Shanghai Lechun BiotechnologySongjiang District, ChinaSingle-use bioprocessing solutions for the biopharmaceutical industry
$110Mvaluation
LePure BiotechWestborough, United StatesSingle-use solutions for the biopharmaceutical industry
$110Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Qiming Venture Partners
WuXi AppTec- RCRunzhang Venture Capital
- SYSuzhou Yihe
Eastern Bell Capital
NRL CapitalShanghai Science and Technology Innovation Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Huimei Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Huimei Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







